rs150712805

Variant summary

Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP4_StrongBS1_SupportingBS2

The NM_032444.4(SLX4):​c.2305G>C​(p.Glu769Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00177 in 1,613,316 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).

Frequency

Genomes: 𝑓 0.0012 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0018 ( 3 hom. )

Consequence

SLX4
NM_032444.4 missense

Scores

1
18

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:9B:3

Conservation

PhyloP100: 0.614

Publications

9 publications found
Variant links:
Genes affected
SLX4 (HGNC:23845): (SLX4 structure-specific endonuclease subunit) This gene encodes a protein that functions as an assembly component of multiple structure-specific endonucleases. These endonuclease complexes are required for repair of specific types of DNA lesions and critical for cellular responses to replication fork failure. Mutations in this gene were found in patients with Fanconi anemia. [provided by RefSeq, Sep 2016]
SLX4 Gene-Disease associations (from GenCC):
  • Fanconi anemia complementation group P
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, G2P
  • Fanconi anemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
  • familial ovarian cancer
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
  • hereditary breast carcinoma
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -9 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.01531893).
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.00116 (176/152324) while in subpopulation NFE AF = 0.0019 (129/68036). AF 95% confidence interval is 0.00163. There are 0 homozygotes in GnomAd4. There are 82 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Homozygotes in GnomAdExome4 at 3 AR,AD gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SLX4NM_032444.4 linkc.2305G>C p.Glu769Gln missense_variant Exon 11 of 15 ENST00000294008.4 NP_115820.2 Q8IY92-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SLX4ENST00000294008.4 linkc.2305G>C p.Glu769Gln missense_variant Exon 11 of 15 5 NM_032444.4 ENSP00000294008.3 Q8IY92-1

Frequencies

GnomAD3 genomes
AF:
0.00116
AC:
176
AN:
152206
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000314
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00190
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000414
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00190
Gnomad OTH
AF:
0.00143
GnomAD2 exomes
AF:
0.00100
AC:
250
AN:
249966
AF XY:
0.00103
show subpopulations
Gnomad AFR exome
AF:
0.000620
Gnomad AMR exome
AF:
0.000464
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00169
Gnomad OTH exome
AF:
0.00115
GnomAD4 exome
AF:
0.00184
AC:
2683
AN:
1460992
Hom.:
3
Cov.:
31
AF XY:
0.00176
AC XY:
1280
AN XY:
726788
show subpopulations
African (AFR)
AF:
0.000389
AC:
13
AN:
33454
American (AMR)
AF:
0.000403
AC:
18
AN:
44696
Ashkenazi Jewish (ASJ)
AF:
0.0000383
AC:
1
AN:
26130
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39700
South Asian (SAS)
AF:
0.000824
AC:
71
AN:
86170
European-Finnish (FIN)
AF:
0.0000375
AC:
2
AN:
53332
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5240
European-Non Finnish (NFE)
AF:
0.00223
AC:
2479
AN:
1111952
Other (OTH)
AF:
0.00164
AC:
99
AN:
60318
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.477
Heterozygous variant carriers
0
164
328
491
655
819
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
104
208
312
416
520
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00116
AC:
176
AN:
152324
Hom.:
0
Cov.:
32
AF XY:
0.00110
AC XY:
82
AN XY:
74478
show subpopulations
African (AFR)
AF:
0.000313
AC:
13
AN:
41578
American (AMR)
AF:
0.00190
AC:
29
AN:
15296
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5176
South Asian (SAS)
AF:
0.000414
AC:
2
AN:
4832
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10612
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00190
AC:
129
AN:
68036
Other (OTH)
AF:
0.00142
AC:
3
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.514
Heterozygous variant carriers
0
9
18
26
35
44
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00188
Hom.:
0
Bravo
AF:
0.00130
TwinsUK
AF:
0.00162
AC:
6
ALSPAC
AF:
0.00363
AC:
14
ESP6500AA
AF:
0.000455
AC:
2
ESP6500EA
AF:
0.00198
AC:
17
ExAC
AF:
0.000914
AC:
111
Asia WGS
AF:
0.000577
AC:
2
AN:
3478
EpiCase
AF:
0.00136
EpiControl
AF:
0.00136

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:9Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Fanconi anemia complementation group P Uncertain:4
May 04, 2022
Fulgent Genetics, Fulgent Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Dec 04, 2020
Baylor Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. -

Oct 14, 2019
Revvity Omics, Revvity
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 27, 2017
Illumina Laboratory Services, Illumina
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -

not provided Uncertain:2Benign:2
Mar 03, 2022
GeneDx
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individuals with breast cancer in published literature (Shah 2013); This variant is associated with the following publications: (PMID: 19596235, 23840564) -

Nov 03, 2021
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Fanconi anemia Uncertain:2
Oct 31, 2022
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 769 of the SLX4 protein (p.Glu769Gln). This variant is present in population databases (rs150712805, gnomAD 0.2%), including at least one homozygous and/or hemizygous individual. This missense change has been observed in individual(s) with breast cancer or head and neck carcinoma (PMID: 23211700, 23840564, 28678401). ClinVar contains an entry for this variant (Variation ID: 407899). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Sep 03, 2021
Sema4, Sema4
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:curation

- -

not specified Uncertain:1
Nov 22, 2021
Genetic Services Laboratory, University of Chicago
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change has been reported in familial breast cancer cases(PMID: 23840564). This sequence change has been described in the gnomAD database with a frequency of 0.16% in the non-Finnish subpopulation (dbSNP rs150712805). The p.Glu769Gln change affects a poorly conserved amino acid residue located in a domain of the SLX4 protein that is known to be functional. The p.Glu769Gln substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to insufficient evidence and the lack of functional studies, the clinical significance of the p.Glu769Gln change remains unknown at this time. -

SLX4-related disorder Benign:1
Apr 22, 2022
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.14
BayesDel_addAF
Benign
-0.60
T
BayesDel_noAF
Benign
-0.63
CADD
Benign
14
DANN
Uncertain
0.99
DEOGEN2
Benign
0.12
T
Eigen
Benign
-0.66
Eigen_PC
Benign
-0.61
FATHMM_MKL
Benign
0.097
N
LIST_S2
Benign
0.61
T
M_CAP
Benign
0.018
T
MetaRNN
Benign
0.015
T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
0.71
N
PhyloP100
0.61
PrimateAI
Benign
0.29
T
PROVEAN
Benign
-1.1
N
REVEL
Benign
0.068
Sift
Benign
0.22
T
Sift4G
Benign
0.27
T
Polyphen
0.065
B
Vest4
0.26
MVP
0.24
MPC
0.26
ClinPred
0.020
T
GERP RS
4.6
Varity_R
0.27
gMVP
0.29
Mutation Taster
=90/10
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs150712805; hg19: chr16-3642722; COSMIC: COSV53569672; COSMIC: COSV53569672; API